felin
immunodefici
viru
fiv
one
common
infecti
agent
affect
cat
worldwid
fiv
human
immunodefici
viru
hiv
share
mani
properti
lifelong
persist
lentivirus
similar
genet
morpholog
virus
propag
tlymphocyt
macrophag
neural
cell
experiment
infect
cat
measur
immun
suppress
sometim
progress
acquir
immunodefici
syndrom
transient
initi
state
infect
follow
long
latent
stage
low
viru
replic
absenc
clinic
sign
termin
stage
virus
caus
sever
immunosuppress
thu
fiv
infect
cat
becom
import
natur
model
studi
hiv
infect
human
especi
evalu
antivir
compound
particular
import
chemotherapeut
studi
close
similar
revers
transcriptas
rt
fiv
hiv
result
high
vitro
suscept
fiv
mani
rttarget
antivir
compound
use
treatment
hivinfect
patient
thu
aim
articl
provid
uptod
review
studi
antivir
treatment
fiv
focus
commerci
avail
compound
human
anim
use
dna
rna
strand
small
differ
molecular
structur
chain
termin
result
nonfunct
nucleic
acid
produc
narti
accept
fals
substrat
viral
enzym
well
cellular
enzym
main
reason
toxic
zidovudin
azt
first
synthes
potenti
anticanc
drug
shown
effect
hiv
becam
first
drug
approv
treatment
hiv
infect
antifiv
activ
zidovudin
assess
numer
vitro
studi
differ
cell
system
first
vitro
studi
carri
north
cowork
show
zidovudin
inhibit
fiv
replic
crandellre
felin
kidney
crfk
cell
suscept
fiv
zidovudin
similar
hiv
evid
fiv
becom
resist
nucleosid
analogu
case
hiv
zidovudineresist
fiv
mutant
aris
six
month
use
singlepoint
mutat
fiv
gene
respons
resist
vivo
zidovudin
reduc
plasma
viral
load
improv
immunolog
clinic
statu
fivinfect
cat
increas
qualiti
life
prolong
life
expect
placebocontrol
trial
zidovudin
improv
stomat
increas
ratio
natur
fivinfect
cat
cat
fivassoci
neurolog
sign
mark
improv
report
within
first
day
therapi
zidovudin
inhibit
rt
also
cellular
polymeras
lead
bone
marrow
suppress
regular
blood
cell
count
necessari
zidovudin
treatment
nonregen
anemia
common
side
effect
cat
bone
marrow
suppress
treat
zidovudin
fivinfect
cat
treat
zidovudin
long
two
year
toler
drug
well
hematocrit
declin
within
three
week
initi
treatment
approxim
baselin
increas
afterward
case
even
without
discontinu
treatment
hematocrit
drop
discontinu
treatment
recommend
anemia
usual
resolv
within
day
side
effect
cat
includ
vomit
anorexia
rare
stavudin
anoth
drug
effect
hiv
approv
treatment
hiv
infect
recent
year
replac
multidrug
treatment
protocol
compound
fewer
side
effect
stavudin
activ
fiv
vitro
mutant
fiv
resist
stavudin
crossresist
sever
antivir
includ
zidovudin
detect
resist
caus
singlepoint
mutat
rtencod
region
pol
gene
vivo
data
fivinfect
cat
publish
didanosin
ddl
shown
activ
hiv
unit
state
second
drug
approv
treatment
hiv
market
sinc
didanosin
activ
fiv
vitro
one
experiment
vivo
studi
fiv
replic
significantli
suppress
anim
treat
didanosin
treatment
contribut
develop
antiretrovir
toxic
neuropathi
lamivudin
also
antihiv
drug
approv
lamivudin
activ
fiv
vitro
combin
zidovudin
lamivudin
synergist
antifiv
activ
cell
cultur
fiv
mutant
resist
lamivudin
contain
point
mutat
rt
gene
select
vitro
show
cross
resist
zidovudin
one
vivo
studi
experiment
fivinfect
cat
treat
highdos
zidovudin
lamivudin
combin
protect
cat
infect
treatment
start
viru
inocul
howev
zidovudinelamivudin
treatment
show
antifiv
activ
chronic
infect
cat
sever
side
effect
includ
fever
anorexia
mark
hematolog
chang
observ
cat
highdos
dualdrug
treatment
thu
highdos
lamivudin
treatment
alon
combin
zidovudin
recommend
natur
fivinfect
cat
emtricitabin
ftc
structur
similar
lamivudin
licens
fda
vitro
antivir
efficaci
demonstr
fiv
date
vivo
studi
fivinfect
cat
abacavir
cyclopropylamino
abc
shown
activ
hiv
belong
fdaapprov
antihiv
compound
abacavir
activ
fiv
vitro
higher
level
cytotox
compound
didanosin
amdoxovir
vivo
studi
drug
fivinfect
cat
similar
narti
ntarti
also
interact
catalyt
site
rt
incorpor
elong
provir
dna
strand
caus
chain
termin
compet
natur
nucleotid
therefor
function
competit
substrat
inhibitor
howev
contrast
narti
ntarti
alreadi
contain
one
phosphat
group
thu
need
two
intracellular
phosphoryl
step
convers
activ
form
first
often
ratelimit
phosphoryl
step
unnecessari
adefovir
ethoxymethylphosphon
acid
pmea
activ
herpesvirus
hepadnavirus
hepat
b
retrovirus
adefovir
licens
hiv
drug
current
avail
oral
formul
bispom
pmea
approv
treatment
chronic
hepat
b
adefovir
belong
acycl
nucleosid
phosphon
alkyl
side
chain
purin
pyrimidin
link
modifi
phosphat
moieti
cp
phosphon
linkag
replac
normal
phosphat
linkag
phosphon
bond
hydrolys
make
difficult
cleav
compound
incorpor
end
elong
provir
dna
strand
adefovir
inhibit
fiv
replic
vitro
sever
studi
investig
efficaci
adefovir
either
experiment
natur
fivinfect
cat
studi
show
efficaci
also
report
sever
side
effect
mainli
nonregen
anemia
recent
studi
adefovir
administ
fivinfect
cat
sixweek
placebocontrol
doubleblind
clinic
trial
ten
cat
receiv
adefovir
mgkg
sc
twice
weekli
ten
cat
receiv
placebo
decreas
provir
viral
load
treat
cat
treat
cat
develop
progress
sometim
lifethreaten
anemia
common
advers
effect
ntarti
show
result
obtain
experiment
studi
alway
appli
field
situat
emphas
import
control
clinic
field
trial
base
lack
efficaci
recent
placebocontrol
field
trial
side
effect
adefovir
recommend
treatment
fivinfect
cat
current
approv
ntarti
treatment
hiv
infect
tenofovir
disoproxil
fumar
tdf
prodrug
tenofovir
r
adenin
r
pmpa
also
member
acycl
nucleosid
phosphon
antivir
spectrum
tenofovir
acid
pmpa
narrow
adefovir
encompass
herpesvirus
confin
hepadnaand
retrovirus
tenofovir
disoproxil
fumar
becom
one
commonli
use
drug
hiv
therapi
sinc
licens
tenofovir
effect
fiv
vitro
evid
tenovovir
might
greater
antifiv
efficaci
less
cytotox
antiretrovir
compound
includ
adefovir
howev
vivo
studi
lack
focu
futur
research
nnrti
highli
specif
activ
retrovirus
includ
fiv
unlik
narti
ntarti
bind
catalyt
site
rt
nonnucleosid
rt
inhibitor
interact
alloster
site
enzym
incorpor
provir
dna
strand
classifi
noncompetit
inhibitor
rt
requir
intracellular
activ
inhibit
enzym
nnrti
group
structur
divers
compound
bind
singl
site
rt
interact
alloster
site
locat
close
proxim
catalyt
site
lead
number
conform
chang
rt
among
effect
chang
caus
reduct
interact
dna
primer
polymeras
domain
enzym
thu
inhibit
viru
replic
three
fdaapprov
nnrti
nevirapin
delavirdin
efavirenz
shown
effect
fiv
vitro
vivo
studi
perform
presum
lack
vitro
efficaci
one
old
nnrti
suramin
broad
antivir
spectrum
use
veterinari
medicin
major
breakthrough
treatment
fiv
would
discoveri
nnrti
activ
fiv
rt
suramin
naphthalen
acid
sodium
salt
sulfat
naphthylamin
trypan
red
deriv
one
oldest
known
antimicrobi
agent
use
antitrypanosom
agent
treatment
tumor
prostat
cancer
also
inhibitori
effect
rt
activ
retrovirus
also
use
human
hiv
infect
suramin
inhibit
rt
interact
templateprim
bind
site
enzym
thu
competit
bind
primer
bind
site
without
nucleosid
analogu
inhibit
templateprim
bind
necessari
dna
elong
suramin
therefor
classifi
nnrti
suramin
effect
felin
leukemia
viru
felv
vivo
thu
could
potenti
activ
fiv
although
investig
suramin
associ
signific
number
sever
side
effect
human
nausea
anaphylact
shock
immedi
reaction
administr
peripher
neuriti
lead
palmarplantar
hyperesthesia
photophobia
skin
reaction
agranulocytosi
hemolyt
anemia
destruct
adren
cortex
later
side
effect
cat
felv
infect
major
advers
effect
suramin
transient
vomit
anorexia
nucleotid
synthesi
inhibitor
prevent
synthesi
nucleotid
variou
mechan
broad
spectrum
activ
associ
mark
toxic
mainli
nonselect
therefor
also
interfer
normal
cellular
nucleotid
synthesi
instanc
foscarnet
interfer
exchang
pyrophosph
deoxynucleosid
triphosph
viral
replic
bind
rt
dna
polymeras
therebi
prevent
nucleotid
synthesi
other
ribavirin
inhibit
inosin
monophosph
dehydrogenas
intracellular
phosphoryl
turn
lead
inhibit
guanosin
monophosph
foscarnet
phosphonoform
acid
pfa
broadspectrum
antivir
activ
dna
rna
virus
includ
retrovirus
fdaapprov
treatment
hivassoci
cytomegalo
herp
simplex
viru
infect
human
foscarnet
usual
administ
intraven
continu
intraven
infus
short
halflif
also
demonstr
cat
oral
administr
drug
possibl
result
irrit
mucou
membran
oral
bleed
foscarnet
mani
side
effect
includ
nephrotox
myelosuppress
human
cat
also
toxic
epitheli
cell
mucou
membran
result
gastrointestin
side
effect
genit
epithelium
ulcer
addit
chelat
variou
cation
lead
hypocalcemia
hypomagnesemia
hypokalemia
vitro
foscarnet
shown
activ
fiv
foscarnetresist
fiv
strain
develop
vivo
studi
fivinfect
cat
carri
like
sever
side
effect
necess
continu
intraven
administr
drug
ribavirin
rtca
mark
vitro
antivir
activ
varieti
dna
rna
virus
system
administr
ribavirin
limit
cat
side
effect
sequestr
ribavirin
within
erythrocyt
result
hemolysi
even
low
dose
drug
use
addit
doserel
toxic
effect
bone
marrow
primarili
megakaryocyt
result
thrombocytopenia
hemorrhag
prolong
ribavirin
treatment
higher
dose
product
erythrocyt
neutrophil
also
suppress
ribavirin
also
induc
hepat
toxic
attempt
decreas
toxic
ribavirin
incorpor
lecithincontain
liposom
administ
lower
dose
success
ribavirin
activ
mani
virus
vitro
includ
fiv
therapeut
concentr
difficult
achiev
vivo
toxic
date
efficaci
ribavirin
investig
fivinfect
cat
receptor
homologuesantagonist
bind
viru
cellular
receptor
lead
inhibit
viral
cellsurfac
bind
receptor
homologuesantagonist
highli
select
hiv
use
veterinari
medicin
except
class
antivir
compound
call
bicyclam
use
cat
fiv
infect
bicyclam
act
potent
select
cxc
chemokin
receptor
antagonist
chemokin
receptor
belong
group
seven
transmembraneprotein
enabl
signal
transmiss
rapid
influx
calcium
cell
essenti
coreceptor
hiv
well
fiv
infect
lymphocyt
bind
bicyclam
prevent
interact
ligand
therebi
inhibit
entri
hiv
fiv
cell
bi
octachlorid
dehydr
bicyclam
prototyp
compound
market
antihiv
drug
use
human
stem
cell
mobil
plerixafor
activ
fiv
vitro
placebocontrol
doubleblind
clinic
trial
treatment
natur
fivinfect
cat
plerixafor
result
signific
decreas
provir
load
treat
cat
compar
placebo
group
concomit
decreas
serum
magnesium
level
produc
clinic
consequ
develop
resist
fiv
isol
plerixafor
occur
treatment
cat
plerixafor
administ
dosag
mgkg
everi
h
monitor
magnesium
calcium
level
perform
regular
interv
treatment
studi
investig
potenti
promis
drug
need
proteas
inhibitor
pi
specif
bind
activ
site
proteas
therefor
prevent
viral
replic
sever
pi
use
success
treatment
hiv
nevertheless
side
effect
develop
viral
resist
found
treatment
therefor
addit
compound
bind
site
activ
site
proteas
develop
tipranavir
n
propi
l
phenyl
trifluoromethyl
approv
use
antihiv
compound
drug
shown
activ
fiv
vitrotipranavir
complet
prevent
fiv
replic
studi
fivinfect
cat
exist
far
studi
need
investig
potenti
tipranavir
natur
infect
cat
drug
shown
activ
fiv
vitro
prevent
fiv
replic
complet
vivo
studi
fivinfect
cat
enzym
integras
catalyz
strand
transfer
join
insert
viral
dna
end
host
cell
chromosom
provir
dna
integr
integr
proviru
persist
host
cell
genom
function
templat
replic
viral
genom
lead
format
new
virus
high
degre
conserv
integraseact
site
across
mani
retrovirus
suggest
fiv
might
also
sensit
integras
inhibitor
integras
inhibitor
act
inhibit
integr
provir
dna
produc
revers
transcript
viral
rna
genom
raltegravir
use
antihiv
compound
drug
shown
activ
fiv
vitro
fiv
less
suscept
raltegravir
hiv
studi
fivinfect
cat
exist
far
although
vivo
studi
efficaci
raltegravir
fivinfect
cat
drug
recent
shown
effect
felv
safe
cat
interferon
ifn
polypeptid
molecul
variou
biolog
function
play
import
role
mediat
antivir
antigrowth
respons
immun
respons
modul
divid
type
type
ii
ifn
antivir
properti
type
ifn
includ
produc
virusinfect
cell
wherea
type
ii
ifn
consist
produc
activ
lymphocyt
natur
killer
cell
respons
recognit
virusinfect
cell
ifn
act
autocrin
paracrin
fashion
induc
antivir
state
noninfect
cell
ifn
bind
specif
cell
surfac
receptor
result
transcript
ifnstimul
gene
product
gene
protein
potent
antivir
properti
interfer
variou
stage
viral
replic
sever
studi
suggest
retrovir
protein
synthesi
affect
ifn
therefor
conclud
antivir
activ
ifn
mainli
relat
interfer
later
stage
viral
replic
cycl
virion
assembl
releas
interferon
also
trigger
virusinfect
cell
undergo
apoptosi
activ
gene
express
apoptosi
prevent
spread
viru
infect
cell
aid
clearanc
viru
infect
human
ifn
manufactur
recombin
dna
technolog
avail
commerci
recombin
felin
market
japan
australia
mani
european
countri
licens
use
cat
dog
recombin
human
antivir
immunemodulatori
activ
activ
mani
dna
rna
virus
two
common
treatment
regimen
use
cat
sc
inject
ukg
everi
h
oral
applic
ukg
everi
h
human
becom
ineffect
three
seven
week
parenter
use
cat
product
neutral
antibodi
antibodi
product
occur
oral
administr
therefor
rout
allow
longer
period
treatment
inactiv
gastric
acid
destroy
trypsin
proteolyt
enzym
duodenum
mean
direct
antivir
effect
unlik
oral
applic
howev
oral
appear
immunomodulatori
activ
stimul
local
lymphoid
tissu
releas
cytokin
lymphat
cell
oropharyng
area
trigger
cascad
immunolog
respons
system
effect
shown
activ
fiv
vitro
although
frequent
use
field
treat
fivinfect
cat
control
studi
evalu
effect
parenter
administr
fivinfect
cat
conduct
use
oral
ill
natur
fivinfect
cat
ukg
appli
oral
mucosa
daili
seven
day
altern
week
six
month
follow
twomonth
break
repetit
sixmonth
treatment
result
improv
clinic
sign
eg
fever
lymphadenopathi
opportunist
infect
placebocontrol
doubleblind
studi
howev
provir
viral
load
monitor
thiat
studi
therefor
imposs
conclud
whether
treatment
inde
effect
fiv
rather
secondari
infect
recombin
felin
correspond
felin
interferon
licens
use
veterinari
medicin
japan
australia
european
countri
use
cat
long
period
without
antibodi
develop
major
sever
side
effect
report
inhibit
fiv
replic
vitro
one
placebocontrol
multicent
studi
investig
effect
parenter
fiv
infect
natur
fivinfect
cat
treat
ukg
sc
q
h
five
consecut
day
find
differ
surviv
rate
treat
cat
howev
improv
clinic
score
includ
eight
categori
clinic
sign
rectal
temperatur
behavior
appetit
thirst
dehydr
mucou
membran
appear
stomat
death
well
improv
laboratori
abnorm
leukopenia
leukocytosi
anemia
occur
anoth
studi
evalu
natur
fivinfect
cat
hous
shelter
clinic
improv
observ
parenter
ukg
sc
q
h
five
consecut
day
three
cycl
studi
lack
placebo
control
studi
hematolog
valu
remain
within
refer
interv
biochem
abnorm
associ
treatment
recent
studi
evalu
use
oral
administr
treatment
eleven
clientown
natur
fivinfect
cat
clinic
sign
treatment
protocol
ucat
po
q
h
consecut
day
administ
cat
owner
histor
retrospect
group
use
control
comparison
ukg
sc
q
h
five
consecut
day
three
cycl
placebo
group
includ
treatment
oral
result
signific
improv
clinic
score
eg
oral
lesion
coat
appear
bodi
condit
score
ocular
discharg
treatment
addit
signific
differ
sc
histor
control
group
po
group
suggest
oral
administr
might
viabl
less
expens
altern
recent
publish
studi
assess
viremia
proviru
load
blood
cytokin
profil
natur
fivinfect
cat
treat
oral
ucat
po
q
h
day
subcutan
ucat
sc
q
h
consecut
day
three
cours
chang
level
viremia
cytokin
level
found
placebo
control
group
includ
fact
viru
load
remain
unchang
clinic
improv
observ
earlier
studi
suggest
effect
secondari
infect
rather
fiv
major
differ
outcom
differ
studi
felin
fivinfect
cat
thu
definit
conclus
drawn
without
addit
random
placebocontrol
doubleblind
studi
includ
suffici
high
number
natur
fivinfect
cat
unfortun
efficaci
antivir
compound
treatment
fiv
cat
gener
poor
durat
treatment
mani
clinic
trial
rel
short
might
inadequ
infect
long
clinic
cours
addit
difficult
compar
treatment
result
cat
infect
experiment
kept
laboratori
condit
pet
cat
infect
field
strain
fiv
therefor
welldesign
doubleblind
placebocontrol
trial
use
antivir
drug
natur
fivinfect
cat
need
determin
efficaci
side
effect
differ
antivir
compound
tabl
treatment
option
antivir
drug
fivinfect
cat
includ
ebm
grade
judgment
avail
efficaci
data
ebm
grade
use
accord
european
advisori
board
cat
diseas
abcd
zidovudin
azt
ye
ye
effect
cat
eg
stomat
neurolog
disord
nd
possibl
effect
toxic
iv
adefovir
pmea
ye
effect
cat
rel
toxic
tenofovir
pmpa
ye
nd
possibl
effect
also
like
rel
toxic
iv
suramin
nd
like
toxic
iv
foscarnet
pfa
ye
nd
effect
vitro
toxic
iv
ribavirin
ye
nd
possibl
effect
toxic
cat
iv
plerixafor
ye
ye
effect
studi
privatelyowen
cat
thu
consid
treatment
